Swiss National Bank’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.27M Hold
220,600
﹤0.01% 1590
2025
Q4
$3.52M Sell
220,600
-2,300
-1% -$32.6K ﹤0.01% 1564
2025
Q3
$2.46M Hold
222,900
﹤0.01% 1751
2025
Q2
$1.89M Sell
222,900
-12,900
-5% -$103K ﹤0.01% 1833
2025
Q1
$1.9M Sell
235,800
-3,200
-1% -$25.9K ﹤0.01% 1795
2024
Q4
$2.15M Sell
239,000
-26,200
-10% -$214K ﹤0.01% 1814
2024
Q3
$1.94M Sell
265,200
-3,300
-1% -$20.5K ﹤0.01% 1881
2024
Q2
$1.53M Hold
268,500
﹤0.01% 1947
2024
Q1
$1.35M Hold
268,500
﹤0.01% 2068
2023
Q4
$2.41M Sell
268,500
-30,200
-10% -$249K ﹤0.01% 1725
2023
Q3
$2.32M Buy
298,700
+19,400
+7% +$190K ﹤0.01% 1742
2023
Q2
$2.7M Buy
279,300
+18,600
+7% +$193K ﹤0.01% 1692
2023
Q1
$2.86M Sell
260,700
-30,500
-10% -$269K ﹤0.01% 1615
2022
Q4
$1.26M Buy
291,200
+5,500
+2% +$31.9K ﹤0.01% 2214
2022
Q3
$2.15M Buy
285,700
+25,100
+10% +$217K ﹤0.01% 1824
2022
Q2
$2.62M Hold
260,600
﹤0.01% 1729
2022
Q1
$3.23M Buy
260,600
+20,400
+8% +$315K ﹤0.01% 1739
2021
Q4
$5.49M Buy
240,200
+13,700
+6% +$325K ﹤0.01% 1408
2021
Q3
$5.01M Buy
226,500
+1,000
+0.4% +$15.9K ﹤0.01% 1461
2021
Q2
$2.93M Sell
225,500
-20,400
-8% -$260K ﹤0.01% 1848
2021
Q1
$3.2M Buy
245,900
+1,900
+0.8% +$27.6K ﹤0.01% 1721
2020
Q4
$3.37M Hold
244,000
﹤0.01% 1609
2020
Q3
$3.58M Buy
244,000
+63,400
+35% +$918K ﹤0.01% 1390
2020
Q2
$2.91M Buy
180,600
+23,200
+15% +$371K ﹤0.01% 1492
2020
Q1
$2.24M Buy
157,400
+4,900
+3% +$86.4K ﹤0.01% 1378
2019
Q4
$3.08M Buy
152,500
+30,500
+25% +$281K ﹤0.01% 1472
2019
Q3
$651K Buy
122,000
+10,200
+9% +$61.7K ﹤0.01% 2266
2019
Q2
$738K Buy
111,800
+13,700
+14% +$87.3K ﹤0.01% 2283
2019
Q1
$637K Hold
98,100
﹤0.01% 2291
2018
Q4
$667K Buy
98,100
+5,700
+6% +$32.9K ﹤0.01% 2229
2018
Q3
$608K Hold
92,400
﹤0.01% 2362
2018
Q2
$530K Hold
92,400
﹤0.01% 2428
2018
Q1
$486K Hold
92,400
﹤0.01% 2381
2017
Q4
$421K Buy
+92,400
New +$513K ﹤0.01% 2443

Other funds holding AUPH

Swiss National Bank's AUPH Position: Q1 2026 in Review

Swiss National Bank held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 220,600 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Swiss National Bank first reported a position in AUPH in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.49M in Q4 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Swiss National Bank held 220,600 shares of Aurinia Pharmaceuticals worth $3.27M as of Q1 2026.
  • Swiss National Bank left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1590 holding.
  • Swiss National Bank first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Swiss National Bank's Aurinia Pharmaceuticals position peaked at $5.49M in Q4 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.